“Get it right the first time; that’s the main thing.” (Joel, 1977)
You finally push your eCTD sequence through the FDA gateway, and you are elated. But then come information requests, technical deficiencies, and downright rejection, which leads to downright dejection. It happens for many, but it does not have to happen to you.
The most common eCTD submission errors include incorrect document placement, broken hyperlinks, poor lifecycle management, missing metadata, inconsistent file naming conventions, PDF compliance issues, inadequate submission readiness reviews, cross-functional inconsistencies, regional submission mistakes, and late involvement of regulatory operations teams.
Here is how to avoid these common errors when submitting your eCTD sequence through the Electronic Submissions Gateway.
“A place for everything and everything in its place.” (Religious Tract Society, 1799)
One of the most common mistakes sponsors make is underestimating the importance of document location within an eCTD submission.
Reviewers rely heavily on the standardized structure of the eCTD to navigate large applications efficiently. When a clinical study report is filed in an unexpected location or a critical CMC document appears in the wrong section, reviewers are forced to spend valuable time searching rather than evaluating.
The document may technically exist in the application, but if it is not where a reviewer expects to find it, its value is diminished. In large submissions containing thousands of files, navigational inconsistencies can quickly become significant obstacles.
The most successful submissions begin with a clearly defined content strategy that ensures every document is placed correctly before publishing ever begins.
“Take it easy on me.” (Little River Band, 1981)
A well-structured eCTD submission should function almost intuitively.
Reviewers move constantly between summaries, source reports, referenced documents, appendices, and supporting datasets. Hyperlinks and bookmarks serve as critical tools that allow them to move efficiently through an application.
When links are broken, bookmarks point to the wrong location, or referenced documents cannot be accessed quickly, the review experience becomes fragmented. What appears to be a minor technical issue from the sponsor's perspective can create repeated interruptions throughout the review process.
The best submissions recognize that navigation is not merely a publishing requirement. It is part of the review experience.
“Time keeps on slipping, slipping, slipping, into the future” (Steve Miller Band, 1976)
If there is one area that consistently creates confusion, it is lifecycle management.
Many organizations dedicate extensive efforts to preparing an original IND, NDA, or BLA but devote far less attention to how documents will be maintained over time. As amendments, supplements, and updates accumulate, errors in replace, append, or delete operations can create uncertainty regarding which version of a document should be considered current.
For FDA reviewers, this uncertainty can be frustrating. Reviewing a dossier is already complex. Determining whether the reviewer is looking at the correct version of a document should never be part of the challenge.
Effective lifecycle management requires long-term planning, consistency, and governance from the earliest stages of development.
“Little things mean a lot.” (Kallen, 1954)
Metadata rarely receives much attention in project meetings. Yet it plays a critical role in how information is organized and retrieved within regulatory systems.
Inaccurate study identifiers, inconsistent document titles, and incomplete metadata may not trigger immediate technical rejection. However, they can make information more difficult to locate and contribute to confusion during review.
Think of metadata as the filing system behind the submission. When it is poorly maintained, even high-quality scientific content becomes harder to access.
As applications grow larger and more complex, the value of accurate metadata becomes increasingly apparent.
“Keep the ball rollin’” (Jay & the Techniques, 1967)
Development programs often span many years and involve numerous contributors.
A submission that begins with strong standards can gradually lose consistency as teams grow, contractors change, and development priorities shift. File naming conventions evolve, terminology becomes inconsistent, and version control becomes more difficult to manage.
This gradual drift is rarely intentional, but it can create challenges for reviewers attempting to understand relationships between documents generated across multiple development phases.
Organizations that maintain strong submission governance throughout a product's lifecycle tend to produce dossiers that are easier to review and maintain.
“Be all that you can be.” (United States Army, 1981)
Although eCTD submissions are electronic, many quality issues still originate within the documents themselves.
Poorly scanned files, non-searchable PDFs, incorrect page orientations, and formatting inconsistencies continue to appear in submissions across the industry. These problems may seem relatively minor, but they force reviewers to spend additional time interacting with the document rather than focusing on the content.
A reviewer should never struggle to search, view, or navigate a document.
The highest-quality submissions treat document usability as an essential component of quality, not an afterthought.
“I check my look in the mirror” (Springsteen, 1984)
A common misconception is that once all required documents have been drafted, the submission is effectively complete.
In reality, content completion and submission readiness are two very different milestones.
Many deficiencies emerge during the final stages of assembly when teams are racing toward a deadline. Missing references, inconsistent versions, publishing errors, and lifecycle discrepancies often remain hidden until a formal readiness review is conducted.
Unfortunately, some organizations skip this step altogether.
A rigorous readiness assessment is often the last opportunity to identify issues before they reach the agency. It may be one of the most valuable quality investments a sponsor can make.
“The more we get together the happier we’ll be.” (Traditional, n.d.)
Modern regulatory submissions are inherently cross-functional.
Clinical teams generate study reports. CMC teams prepare manufacturing documentation. Nonclinical groups contribute toxicology and pharmacology information. Regulatory professionals ultimately integrate all of these components into a cohesive application.
Without strong coordination, inconsistencies inevitably emerge. Product names differ between modules, study identifiers fail to match referenced reports, and key information may be described differently across documents.
These discrepancies create uncertainty at precisely the moment reviewers are seeking clarity.
Strong regulatory operations teams serve as a central coordinating function, ensuring consistency across the entire application.
“Different strokes for different folks” (Sly & the Family Stone, 1968)
As development becomes increasingly global, sponsors often seek efficiencies by leveraging content across multiple regulatory regions.
While this approach makes sense, it can lead to problems when regional requirements are assumed to be interchangeable.
Submission structures, validation expectations, and technical requirements continue to evolve across health authorities. What works seamlessly in one region may require modification elsewhere.
Successful sponsors recognize that global harmonization has advanced considerably, but local requirements still matter.
“Both afraid to say we're just too far away from being close together from the start” (Russell, 1972)
Perhaps the most significant deficiency is not technical at all.
Many organizations continue to view regulatory operations as a publishing function that becomes relevant near a submission deadline. By the time regulatory operations teams become involved, many critical decisions have already been made.
In reality, regulatory operations influences everything from document strategy and lifecycle planning to submission architecture, content organization, and reviewer usability.
When operations experts are engaged early, potential issues can be identified long before they become submission risks. When they are brought in at the end, teams often discover preventable problems at the most challenging possible moment.
The most successful organizations treat regulatory operations as a strategic partner throughout development, not as the final step before submission.
The success of an eCTD submission is not measured solely by whether it passes validation or reaches the FDA on time. Its true value lies in how effectively it supports review. A well-structured, reviewer-friendly submission allows FDA reviewers to quickly find, understand, and evaluate the information they need, reducing unnecessary questions and minimizing avoidable delays. Achieving that level of quality requires more than technical compliance. It demands expertise in eCTD architecture, lifecycle management, submission strategy, and reviewer expectations. By partnering with experienced regulatory operations specialists, sponsors can help ensure that the strength of their science is communicated clearly, efficiently, and without preventable operational barriers, ultimately supporting a smoother and more effective regulatory review process.
Jay & the Techniques. (1967). Keep the Ball Rolling. «single». Smash Records.
Joel, B. (1977). Get It Right the First Time. The Stranger. Columbia Records.
Kallen, K. (1954). Little Things Mean a Lot. «single». Decca Records.
Little River Band. (1981). Take It Easy on Me. Time Exposure. Capitol Records.
Religious Tract Society. (1799). The Naughty Girl Won. London: Religious Tract Society.
Russell, L. (1972). This Masquerade. Carney. Shelter Records.
Sly & the Family Stone. (1968). Everyday People. Stand! Epic Records.
Springsteen, B. (1984). Dancing in the Dark. Born in the U.S.A. Columbia Records.